Francesca Bruce
Senior Writer
Francesca writes about a broad range of policy and regulatory topics, including intellectual property rights. However, her main areas of expertise are pricing and reimbursement and how medicines may or may not make it to patients. She writes about developments in Europe and is also expanding coverage in emerging markets, including Latin America and the Middle East. Francesca writes for Pink Sheet, Scrip and In Vivo.
Latest From Francesca Bruce
Premature Filings Add To EU Regulatory Resource Challenge
The pharmaceutical legislation overhaul offers some solutions to the problem of immature applications.
Early Advice Could Help Companies Maintain EU Conditional Marketing Authorizations
The number of conditional marketing authorization non-renewals could increase.
El Salvador Sets Up New Regulatory Body To Oversee Medicines & Devices
El Salvador has approved a new law that will establish a new regulatory body responsible for authorizing medicines and setting prices.
UK Voluntary Pricing Deal: Commercial Framework To Better Align With New Regulatory Pathways
NHS England has committed to two pilots on innovative pricing models for advanced therapies under the UK’s new voluntary pricing agreement for new medicines.
El Salvador Sets Up New Regulatory Body To Oversee Medicines & Devices
El Salvador has approved a law that will establish a new regulatory body responsible for authorizing medicines and setting prices.
Hemgenix: European Countries Start Joint HTA Of Another Costly Gene Therapy
CSL’s Hemgenix is the latest expensive gene therapy to come under scrutiny from the BeNeLuxA cross-country coalition.